X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
melanoma (14) 14
oncology (11) 11
index medicus (9) 9
ipilimumab (8) 8
humans (7) 7
adult (6) 6
aged (6) 6
immunology (6) 6
middle aged (6) 6
cancer (5) 5
female (5) 5
male (5) 5
metastasis (5) 5
overall survival (5) 5
survival (5) 5
association (4) 4
best overall response (4) 4
care and treatment (4) 4
ctla-4 variants (4) 4
genetic aspects (4) 4
melanoma - metabolism (4) 4
metastatic melanoma (4) 4
predictive/prognostic factor (4) 4
young adult (4) 4
adverse events (3) 3
aged, 80 and over (3) 3
cancer patients (3) 3
cancer therapies (3) 3
chemotherapy (3) 3
endothelial growth-factor (3) 3
health aspects (3) 3
immunotherapy (3) 3
italy (3) 3
melanoma - drug therapy (3) 3
melanoma - genetics (3) 3
mutation (3) 3
neoplasms. tumors. oncology. including cancer and carcinogens (3) 3
patients (3) 3
predictive (3) 3
prognosis (3) 3
research paper (3) 3
therapy (3) 3
tumors (3) 3
usage (3) 3
analysis (2) 2
antineoplastic agents - therapeutic use (2) 2
apoptosis (2) 2
bevacizumab (2) 2
biomarkers (2) 2
cell biology (2) 2
cell line, tumor (2) 2
cell receptors (2) 2
circulating tumor cells (2) 2
ctla-4 protein (2) 2
cutaneous melanoma (2) 2
dabrafenib (2) 2
drug resistance, neoplasm (2) 2
drug therapy (2) 2
elderly-patients (2) 2
health care sciences & services (2) 2
invasion (2) 2
invasiveness (2) 2
kaplan-meier estimate (2) 2
medicine & public health (2) 2
melanoma - mortality (2) 2
melanoma - pathology (2) 2
melanoma molecular biomarker (2) 2
melanoma relapse (2) 2
metastases (2) 2
neoplasm metastasis (2) 2
neoplasms (2) 2
neoplasms - drug therapy (2) 2
nursing (2) 2
nursing management/nursing research (2) 2
pain medicine (2) 2
pax3 (2) 2
pembrolizumab (2) 2
prognostic factor (2) 2
proliferation (2) 2
proto-oncogene proteins b-raf - genetics (2) 2
proto-oncogene proteins b-raf - metabolism (2) 2
psychological distress (2) 2
qrt-pcr (2) 2
rehabilitation (2) 2
rehabilitation medicine (2) 2
research (2) 2
skin neoplasms - mortality (2) 2
solid tumors (2) 2
time factors (2) 2
treatment outcome (2) 2
vascular endothelial growth factor (2) 2
5-fluorouracil toxicity (1) 1
abridged index medicus (1) 1
acquired resistance (1) 1
activation (1) 1
adaptor proteins, signal transducing - metabolism (1) 1
adenosine triphosphatases - metabolism (1) 1
adipose-tissue (1) 1
advanced melanoma (1) 1
agent (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncotarget, ISSN 1949-2553, 04/2018, Volume 9, Issue 27, pp. 18997 - 19005
Metastatic melanoma carrying BRAF mutations represent a still unmet medical need as success of BRAF inhibitors is limited by development of resistance.... 
Tumor marker | Metastatic melanoma | Prognosis | Resistance to therapy | NAMPT
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 45, pp. 79809 - 79815
As diverse therapeutic options are now available for advanced melanoma patients, predictive markers that may assist treatment decision are needed. A model... 
Biomarker | Ipilimumab | Eosinophil | Melanoma | Predictive | SURVIVAL | TRIAL | METASTATIC MELANOMA | PEMBROLIZUMAB | ipilimumab | predictive | melanoma | TO-LYMPHOCYTE RATIO | eosinophil | biomarker | CELL BIOLOGY
Journal Article
Journal Article
Cancer Investigation, ISSN 0735-7907, 5/2014, Volume 32, Issue 4, pp. 144 - 149
Journal Article
International Journal of Oncology, ISSN 1019-6439, 04/2016, Volume 48, Issue 4, pp. 1581 - 1589
The placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family, which shares with VEGF-A the tyrosine kinase receptor... 
bevacizumab | melanoma | vasculogenic mimicry | PlGF | neuropilin-1 | SURVIVAL | ACTIVATION | VEGF | INHIBITS GROWTH | FACTOR RECEPTOR-1 | INVASIVENESS | AGENT | BREAST-CANCER CELLS | ONCOLOGY | ENDOTHELIAL-CELLS
Journal Article
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, ISSN 1756-9966, 06/2019, Volume 38, Issue 1, pp. 272 - 24
BackgroundDevelopment of resistance to inhibitors of BRAF (BRAFi) and MEK (MEKi) remains a great challenge for targeted therapy in patients with BRAF-mutant... 
MIGRATION | SURVIVAL | THERAPEUTICS | MICRORNA-126 | proliferation | CANCER CELLS | BRAF inhibitors | melanoma | miR-126-3p | DRUG-RESISTANCE | acquired resistance | invasiveness | METASTATIC MELANOMA | ONCOLOGY | PATHWAY | BRAF INHIBITOR RESISTANCE | ENDOTHELIAL GROWTH-FACTOR | Cell proliferation | Prognosis | MicroRNA | Gene mutations | Melanoma | Genetic aspects | Research
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 01/2019, Volume 68, Issue 1, pp. 97 - 107
Journal Article
The Oncologist, ISSN 1083-7159, 06/2019, Volume 24, Issue 6, pp. e327 - e337
Background Patients with a history of autoimmune diseases (AIDs) have not usually been included in clinical trials with immune checkpoint inhibitors. Materials... 
Autoimmune disease | Immune checkpoint inhibitors | Immunotherapy | Performance status | Anti‐programmed death‐1 | Sex | Anti-programmed death-1 | CRITERIA | MANAGEMENT | EFFICACY | IMMUNE-CHECKPOINT INHIBITORS | THERAPY | ONCOLOGY | ADVANCED MELANOMA | SEX-DIFFERENCES | ELDERLY-PATIENTS | ASSOCIATION | ADVERSE EVENTS
Journal Article
Journal Article